AI주식인사이트AI Stock Insight
C

바디텍메드

206640KOSDAQ의료용품 및 기타 의약 관련제품 제조업

54.5 / 100

Reference Date: 2026-07-24

Financial Score24.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit metrics are weak. Rose 9.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Bodytekmed operates two business segments: immune diagnostic cartridges and diagnostic devices. It supplies a wide range of products, including CRP, PCT, and D-Dimer cartridges, as well as ichroma and AFIAS series diagnostic equipment, to global markets. Following the COVID-19 pandemic, the company expanded its antigen testing products and continues to launch high-value items like ST2 and TDM diagnostic kits. The AFIAS series, featuring automated functionality, is expected to drive sales growth due to enhanced user convenience.

Number of Employees

601people

Average Salary

49.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
9.81Industry Average 15.186.5Point

Lower than industry avg (good)

PBR
0.96Industry Average 1.094.0Point

In line with industry avg

ROE
10.22Industry Average -4.893.5Point

Well below industry avg

Debt Ratio
5.76Industry Average 6.864.0Point

In line with industry avg

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.1% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲1.3% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 12.5% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 10,700Won52-week high 14,80052-week low 9,800
1-month return5.0Point

1m +9.18% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0